Ascentage Pharma To Present Five Preclinical Studies From Innovative Pipeline At American Association Of Cancer Research (AACR) Annual Meeting 2025
The data to be presented encompasses five of the company's novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...
Dundee Corporation Delivers On Strategic Goals And Reports 2024 Profit
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) --“2024 marked a transformative year for Dundee with broad positive performance in our core strategy and key ...